title: Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
abstract: Hydroxyurea (HU) is the sole approved pharmacological therapy for sickle cell disease (SCD). Higher levels of fetal hemoglobin (HbF) diminish deoxygenated sickle globin polymerization in vitro and clinically reduce the incidence of disease morbidities. Clinical and laboratory effects of HU largely result from induction of HbF expression, though to a highly variable extent. Baseline and HU-induced HbF expression are both inherited complex traits. In children with SCD, baseline HbF remains the best predictor of drug-induced levels, but this accounts for only a portion of the induction. A limited number of validated genetic loci are strongly associated with higher baseline HbF levels in SCD. For induced HbF levels, genetic approaches using candidate single-nucleotide polymorphisms (SNPs) have identified some of these same loci as being also associated with induction. However, SNP associations with induced HbF are only partially independent of baseline levels. Additional approaches to understanding the impact of HU on HbF and its other therapeutic effects on SCD include pharmacokinetic, gene expression-based, and epigenetic analyses in patients and through studies in existing murine models for SCD. Understanding the genetic and other factors underlying the variability in therapeutic effects of HU for pediatric SCD is critical for prospectively predicting good responders and for designing other effective therapies.
authors.affiliation: Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Columbia University, New York, New York.
authors.forename: Nancy S
authors.initials: NS
authors.lastname: Green
authors.affiliation: G.H.Sergievsky Center, Department of Neurology, Columbia University, New York, New York.
authors.forename: Sandra
authors.initials: S
authors.lastname: Barral
mesh_terms: D000367:Age Factors; D000755:Anemia, Sickle Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D000818:Animals; D000986:Antisickling Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005319:Fetal Hemoglobin / Q000235:genetics / Q000378:metabolism; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000986:Antisickling Agents; D005819:Genetic Markers; D005319:Fetal Hemoglobin; D006918:Hydroxyurea